Ovarian, Fallopian Tube, Primary Peritoneal Cancer - ZN-c3-005: GOG 3066
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT05128825?id=denali&rank=2
Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut
Contacts: Sierra Cugno: Sierra.Cugno@hhchealth.org; Siobhan Reilly: Siobhan.Reilly@hhchealth.org